	US 12,486,332 B2
	Anti-ERBB3 antibodies
Sylvie Vincent, Somerville, MA (US); William M. Winston, Jr., Marlborough, MA (US); Fang Wang, Belmont, MA (US); Solly Weiler, Newton, MA (US); Kristan Meetze, Lexington, MA (US); Lyne Breault, Roslindale, MA (US); Steve Bottega, Cambridge, MA (US); Ting Chen, Acton, MA (US); Michael DePrima, Somerville, MA (US); Christina Fleet, Melrose, MA (US); Steven Tyler, Boston, MA (US); Jin-Kyeung Woo, Newton, MA (US); and Jeno Gyuris, Lincoln, MA (US)
Assigned to AVEO Pharmaceuticals, Inc., Boston, MA (US)
Filed by AVEO Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Apr. 26, 2023, as Appl. No. 18/307,638.
Application 18/307,638 is a division of application No. 16/667,056, filed on Oct. 29, 2019, granted, now 11,680,108.
Application 15/448,164 is a division of application No. 14/987,374, filed on Jan. 4, 2016, granted, now 9,598,498, issued on Mar. 21, 2017.
Application 14/987,374 is a division of application No. 13/919,582, filed on Jun. 17, 2013, granted, now 9,228,021, issued on Jan. 5, 2016.
Application 13/919,582 is a division of application No. 13/082,852, filed on Apr. 8, 2011, granted, now 8,481,687, issued on Jul. 9, 2013.
Application 16/667,056 is a continuation of application No. 15/448,164, filed on Mar. 2, 2017, granted, now 10,494,441, issued on Dec. 3, 2019.
Claims priority of provisional application 61/322,712, filed on Apr. 9, 2010.
Prior Publication US 2023/0365710 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 39/395 (2006.01); C07K 16/32 (2006.01); C12N 15/00 (2006.01); C12N 15/13 (2006.01); A61K 39/00 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01)

CPC C07K 16/32 (2013.01) [C07K 16/30 (2013.01); A61K 39/39558 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 5/10 (2013.01); C12N 15/00 (2013.01); C12N 15/63 (2013.01)]

15 Claims

1. An isolated antibody that binds human ErbB3 comprising:

(i) an immunoglobulin heavy chain variable region comprising a CDR_H1comprising the amino acid sequence of SEQ ID NO: 41, a CDR_H2comprising the amino acid sequence of SEQ ID NO: 42, and a CDR_H3comprising the amino acid sequence of SEQ ID NO: 43; and

(ii) an immunoglobulin light chain variable region comprising a CDR_L1comprising the amino acid sequence of SEQ ID NO: 44, a CDR_L2comprising the amino acid sequence of SEQ ID NO: 45, and a CDR_L3comprising the amino acid sequence of SEQ ID NO: 46.